Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

A. Sekeres, Mikkael; P. Maciejewski, Jaroslaw; Giagounidis, Aristoteles; Wride, Kenton; Knight, Robert; Raza, Azra; F. List, Alan

doi:10.1200/jco.2007.15.5770

Public

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

Published in Journal of Clinical Oncology • Nov 18, 2008

Authors:

Mikkael A. Sekeres

Jaroslaw P. Maciejewski

Aristoteles Giagounidis

Abstract

PURPOSE: Patients with myelodysplastic syndromes (MDS) often require treatment with growth factors (GFs) or non-GF therapies. One non-GF drug, lenalidomide, is particularly effective at achieving transfusion independence (TI) in patients with lower-risk MDS with the del(5q) cytogenetic abnormality. ...

Subject

Lenalidomide

Medicine

Myelodysplastic syndromes

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!